AstraZeneca and MedImmune enter consortium to find new treatments for chronic kidney disease

The RPC2 consortium (renal precompetitive consortium) will combine extensive clinical and molecular data collected by Professor Matthias Kretzler at the University of Michigan with the R&D expertise of the pharmaceutical industry.

Professor Kretzler has established a renal database containing information from more than 1,000 patients, as well as from multiple animal models of CKD to advance research into the condition. The consortium will access the database to explore key pathways that drive the progression of CKD and identify potential new targets for medicines. Each member will contribute with its bioinformatic and scientific capabilities to the consortium to build on the analyses already begun by the University of Michigan. Members retain the right to explore targets of interest independently.

“We have to find ways to bring new therapies to our patients faster,” said Professor Kretzler. “The RPC2 gives us the opportunity to combine large-scale clinical and molecular data exploration with the development expertise of the pharmaceutical industry.”

Marcus Schindler, Head of the Cardiovascular and Metabolic Diseases (CVMD) Innovative Medicines Unit, AstraZeneca, said: “For AstraZeneca, joining this consortium represents a great step forward in our aspiration to become a leader in the treatment of CKD. We believe that knowledge generated in the consortium will lead to an expansion of our portfolio with targets that have a strong patient-based foundation.”

Cristina Rondinone, Head of Cardiovascular and Metabolic Diseases Innovative Medicines at MedImmune said: “The consortium brings several combined years of drug discovery and scientific expertise from academic and pharmaceutical partners, which will accelerate discovery of new pathways to help us deliver meaningful biologic medicines for patients with chronic kidney diseases.”

AstraZeneca’s participation in the consortium complements an existing agreement between the company and the University of Michigan in which targets from AstraZeneca’s cardiovascular and metabolic disease portfolio are validated for their potential in treating CKD. It will aim to discover new targets and drive re-purposing of existing medicines based on new understanding of disease progression.


About CKD

Chronic kidney disease (CKD) affects more than 200 million people worldwide and more than 30 million adults in the U.S. Although it can occur at any age, it becomes more common in aging populations and the prevalence is increasing. Anemia is a common complication of CKD and is associated with significant morbidity and mortality in dialysis and non-dialysis populations. In addition, CKD can be both a cause and a consequence of cardiovascular disease and is now a critical worldwide healthcare issue that represents a large and growing unmet medical need.  Currently, no curative treatment or ability to stop kidney deterioration in patients with CKD exists with the exception of kidney transplantation.

About the University of Michigan

The University of Michigan Health System creates the future of health care through medical education, patient care and research. UMHS is a community of more than 26,000 faculty, staff, trainees and volunteers, including 3 hospitals and 40 outpatient locations. The University of Michigan Medical School consistently ranks among the top research universities in the United States and world. With one of the nation's largest research budgets, The University of Michigan finds new ways to understand, diagnose, treat, manage and prevent many human diseases.


*******

Media Enquiries

Neil Burrows   UK/Global      +44 20 7604 8032

Karen Birmingham    UK/Global       +44 20 7604 8120

Jacob Lund    Sweden          +46 8 553 260 20

Michele Meixell     US                  +1 302 885 2677
____________________________________________________